routine childhood immunisations at 2 months and neither BCG nor the beginning of the childhood course is postponed.
Information is not available on the age up to which it is safe to give BCG immunisation without a prior tuberculin test. The Joint Committee on Vaccination and Immunisation has agreed, however, that in the absence of any suggestion of recent contact with tuberculosis a cut off point at 3 months would be sensible. 14 Tuberculin testing of neonates is less common than testing of schoolchildren, but it is surprising that in five districts no action was recommended for grade 2 results in this age group. Indeed in neonates even a grade 1 result should be considered with suspicion, especially if there is any recent history of contact with tuberculosis.
Whoever takes the leading role in devising a district's policy for BCG immunisation, it is appropriate that the consultant in communicable disease control (or other public health physician, if a consultant is not in post) as well as the district immunisation coordinator consult with a chest physician (or physician with an interest in respiratory medicine) about the policy for the schools programme and with a paediatrician on the policy for the programme in neonates. In addition, it would seem prudent to have such policies reviewed by either a district control of infection committee or an immunisation comnuittee.
We thank Mrs M Bezzant for her administrative support, Ms F Majid for her statistical advice, and Drs K Citron, J Leese, and C Skinner for their helpful comments on this manuscript. We are also grateful to all the immunisation coordinators, consultants in communicable disease control, and others who provided the information for this national survey.
Subjects-Repeat donors ( As the prevalence of HIV antibody was similar in repeat and first time donors before exclusion of known positives from the repeat donor population (unpublished data) the incidence of HIV infection in the two groups should be similar. The calculated incidence rates of HIV antibody in repeat donors were applied to the first time donor population, and rates of potentially infected blood units were calculated for both groups as previously described.2
For the calculation of incidence of HIV infection it was assumed that each regular donor gave blood every three months (Centre National de Transfusion Sanguine, unpublished data); that detectable antibody developed within eight weeks of HIV infection; that the probability of a regular donor becoming infected with HIV was equal throughout the year; and that blood donations were equally distributed over the year. Figure 2 shows the donation of blood by regular donors. For seroconversion to be detected a donor must be tested at least twice. Donation of blood every three months results in each donor being tested four times during the year and having three separate intervals of three months each, during which seroconversion could be detected. The equal distribution of blood donations over the year means the population of regular donors could be considered as three separate cohorts, each giving blood every three months. For the three cohorts, therefore, there would be a total of nine periods during which HIV infection could be detected. Incidence rates generated in this way are for a time period of nine months and need to be adjusted for annual incidence.
We looked for seroconversions in regular donors giving blood between January and July inclusive, which encompasses 4/9 periods during which seroconversion could be detected throughout the year.
DETERMINATION OF FALSE NEGATIVE RESULTS
To calculate a range of number of units of blood incorrectly considered to be negative for HIV antibody, test sensitivity levels of 99%, 99-5%, and 99-9% were applied to the observed levels of seroprevalence in units from first time donors and repeat donors. Table III shows the number of HIV antibody positive units that would be incorrectly labelled negative according to different levels of laboratory sensitivity. At a sensitivity of 99%, 1-3 of the units collected from repeat donors would have been infected, and 5-6 units from first time donors. The respective rates would be 0-2/1000 units from repeat donors and 1-1/1000 units from first time donors. There is a need for studies in areas ofhigh prevalence of HIV to measure directly the risks associated with blood transfusion that we have attempted to estimate. Tests for HIV p24 antigen should be evaluated, and for selected situations autotransfusions and use of blood substitutes may be feasible. Such interventions, however, will not be widely applicable in the developing world. The two most important conclusions from this study are that more attention is needed in Africa in choosing blood donors with a low incidence of HIV infection, and that absolute emphasis must be placed on avoiding transfusion in all but those whose need is most dire. This may require creation of national blood transfusion advisory committees to establish guidelines for the rational use of blood and mechanisms for their implementation. 17 We thank Drs John Ward, Harrison Stetler, Helene Gayle, and James Curran for discussion, and we acknowledge the valuable comments and suggestions of the anonymous statistical referee. 
Results

HIV SEROPREVALENCE IN FIRST TIME AND REPEAT DONORS
I TABLE IV-Estimated overall risk of blood donations with HIV infected blood in Abidjan despite HIV antibody screening Repeat donors First time donors Total (No of (No of (No of units=5831
